A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report

BACKGROUND: Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal cell carcinoma and soft tissue sarcoma. Liver toxicity is a common side effect for this class of agents. The current opinion is that in case of severe liver toxicity pazopanib should be interrupted and restart...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschoor, Arie J., Warmerdam, Fabiënne A. R. M., Bosse, Tjalling, Bovée, Judith V. M. G., Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778698/
https://www.ncbi.nlm.nih.gov/pubmed/29357824
http://dx.doi.org/10.1186/s12885-018-3999-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778698/
https://www.ncbi.nlm.nih.gov/pubmed/29357824
http://dx.doi.org/10.1186/s12885-018-3999-0

Ejemplares similares